Delivery Order SPE2DB24D1021-SPE2DB25FFAPV
- Not listed
- The Defense Logistics Agency awarded a $10,858.52 delivery order to AmerisourceBergen Drug Corp for BIMZELX 320 mg/2 ml auto-injector pharmaceutical product on July 25, 2025, with final delivery scheduled for July 28, 2025. This firm fixed-price, non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare vendor that...
- The Defense Logistics Agency awarded a delivery order valued at $43,770.93 to AmerisourceBergen Drug Corp for the supply of BIMZELX 320 mg/2 mL auto-injector units. The contract, which was competitively awarded without set-aside restrictions, carries a firm fixed price structure and an ultimate completion date of August 18, 2025. Performance of this delivery order will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $35K to AmerisourceBergen Drug Corp for BIMZELX 320 mg/2 mL auto-injector pharmaceutical products. This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by September 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken....
- The Defense Logistics Agency awarded a $11,394.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml auto-injector product, with an ultimate completion date of August 6, 2025. This competitively awarded contract, with no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical...
- The Defense Logistics Agency awarded a $69,112.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml auto-injectors, with an ultimate completion date of August 5, 2025. This competitive award, which was not set-aside, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of BIMZELX 320 mg/2 ml auto-injector units valued at $9,855.21 with completion by August 1, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for BIMZELX 160 mg/mL auto-injectors, a specialty pharmaceutical product, with a ceiling value of $26,727.10. This firm fixed-price delivery order, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a non-competitive set-aside award. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $74,689.95 to AmerisourceBergen Drug Corp for BIMZELX 160 mg/mL auto-injector supplies. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and performance location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, serves as a critical vendor for federal military and veteran healthcare systems through the...
- The Defense Logistics Agency awarded a $23,855.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BIMZELX 320 mg/2 mL auto-injector pharmaceutical product on September 11, 2025, with an ultimate completion date of September 12, 2025. This competitively awarded contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $45,373.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BIMZELX 160 mg/ml auto-injectors, with a completion date of July 22, 2025. This non-set-aside contract represents a direct procurement of a specialized pharmaceutical product to support federal healthcare needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAPVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,057.06 to AmerisourceBergen Drug Corp for BIMZELX 320 mg/2 mL auto-injector pharmaceutical products. This firm fixed-price, competitively awarded delivery order was issued on September 12, 2025, with an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competed among qualified vendors in the open market. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The company's extensive contract portfolio with DLA demonstrates its capability to fulfill diverse pharmaceutical procurement requirements, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.1k | 9/12/25 |